Dld Asset Management, LP Immuno Gen, Inc. Call Options Transaction History

Dld Asset Management, LP

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 12, 2022	SELL	$3.15 - $5.76 $78,750 - $144,000	-25,000 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$4.26 - $7.48 $106,500 - $187,000	25,000 New	25,000 $119,000
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $180,000 - $330,000	-100,000 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$2.41 - $5.91 $241,000 - $591,000	100,000 New	100,000 $270,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Dld Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Dld Asset Management, LP with notifications on news.